Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
Immunoadsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase.
Th17 and Non-Classic Th1 Cells in Chronic Inflammatory Disorders: Two Sides of the Same Coin.
Bringing CLARITY to gray matter atrophy.
Prostaglandin F2α FP receptor inhibitor reduces demyelination and motor dysfunction in a cuprizone-induced multiple sclerosis mouse model.
Prevalence and Impact of Pain in Adults Aging With a Physical Disability: Comparison to a US General Population Sample.
Protein kinase C polymorphisms and vitamin D levels in multiple sclerosis.
Determinant spreading and the dynamics of the autoimmune T-cell repertoire.
Patient taking Novartis MS pill developed rare disease
Chronic illness and return to work: a social cognitive perspective.
Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors.
Exploring the role of interleukin-22 in neurological and autoimmune disorders.
Prediction of disability progression in fingolimod-treated patients.
Coping Mediates and Moderates the Relationship Between Executive Functions and Psychological Adjustment in Multiple Sclerosis .
Multiple sclerosis: Diurnal variations in serum markers of inflammation-an avoidable source of bias in MS studies?
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis.
Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.
What is the true clinicopathologic spectrum of neuromyelitis optica?-Reply.
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
SLAM-SAP Signaling Promotes Differentiation of IL-17-Producing T Cells and Progression of Experimental Autoimmune Encephalomyelitis.
Melatonin treatment improves primary progressive multiple sclerosis: a case report.
Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females.
Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis.
Emotional Intelligence (EI) of Patients with Multiple Sclerosis (MS).
Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS.
Pages
« first
‹ previous
…
412
413
414
415
416
417
418
419
420
…
next ›
last »